Table 3.

Summary of adverse events (AEs) by treatment group

Event	NeuroEPO plus 0.5 mg (n = 57)	NeuroEPO plus 1.0 mg (n = 56)	Placebo (n = 57)
Overview of AE — no. (%)
Participants with any AE	5 (8.8)	3 (5.4)	3 (5.3)
AE related to neuroEPO plus or placebo	1 (1.8)	0	0
Serious AE	3 (5.3)	0	3 (5.3)
Death (not related to treatment)	1 (1.8)	0	1(1.8)
Participants with ≥ 1 serious AE	1 (1.8)	0	1(1.8)
AE that occurred in either group
Bronchopneumonia	1(1.8)	0	1(1.8)
Pulmonary embolism	1 (1.8)	0	0
Numbness upper right member	1 (1.8)	0	0
Bronchopneumonia	1 (1.8)	0	0
Fall down	0	0	1(1.8)
Headache	1 (1.8)	0	0
Nasal congestion	1 (1.8)	0	0
Constipation	1 (1.8)	0	0
Dehydration	0	0	1(1.8)
Pain due to fall down	0	0	1(1.8)
Flu status	0	1 (1.8)	0
Hypertension	0	1 (1.8)	0
Hematoma due to fall down	0	0	1 (1.8)
Urinary sepsis	0	1 (1.8)	0
Irritability	0	0	1 (1.8)
Palpitations	1 (1.8)	0	0
Deep venous thrombosis	1 (1.8)	0	0
Vomiting	1 (1.8)	1 (1.8)	1 (1.8)
Diarrhea	0	1 (1.8)	0

The analysis was performed in the safety population, which included participants who received at least one dose of neuroEPO or placebo

AEs Adverse events, No. Number